Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer

Clinical Cancer Research

Volumn 15, Issue 12, 2009, Pages 4138-4146

  Rajeshkumar, N V ^a   Tan, Aik Choon ^a   De Oliveira, Elizabeth ^a   Womack, Chris ^b   Wombwell, Helen ^b   Morgan, Shethah ^b   Warren, Madhuri V ^c   Walker, Jill ^b   Green, Tim P ^b   Jimeno, Antonio ^a   Messersmith, Wells A ^a   Hidalgo, Manuel ^a,d,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c Pathology Diagnostics Ltd   (United Kingdom)

^d Hospital Madrid Norte Sanchinarro   (Spain)

^e Department of Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL ADHESION KINASE; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PAXILLIN; PROTEIN TYROSINE KINASE; STAT3 PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IGFBP2 GENE; IMMUNOHISTOCHEMISTRY; LRRC19 GENE; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIOXOLES; FEMALE; FOCAL ADHESION KINASE 1; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PAXILLIN; PROTO-ONCOGENE PROTEINS PP60(C-SRC); QUINAZOLINES; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67449156112     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3021     Document Type: Article

References (43)

1. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004;4:470-480 (Pubitemid 38745532)
2. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-358 (Pubitemid 36791891)
3. Warmuth M, Damoiseaux R, Liu Y, Fabbro D, Gray N. SRC family kinases: potential targets for the treatment of human cancer and leukemia. Curr Pharm Des 2003;9:2043-2059 (Pubitemid 37139082)
4. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602:114-130 (Pubitemid 34521791)
5. Ito H, Gardner-Thorpe J, Zinner MJ, Ashley SW, Whang EE. Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery 2003;134:221-226 (Pubitemid 37070342)
6. Yezhelyev MV, Koehl G, Guba M, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res 2004;10:8028-8036 (Pubitemid 39587544)
7. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19:5636-5642
8. Avizienyte E, Frame MC. Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol 2 005;17:542-547 (Pubitemid 41267169)
9. Hiscox S, Jordan NJ, Morgan L, Green TP, Nicholson RI. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin Exp Metastasis 2007;24:157-167 (Pubitemid 46850227)
10. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81-83
11. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-5272 (Pubitemid 44497237)
12. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 1993;91:53-60. (Pubitemid 23037252)
13. Lee D, Gautschi O. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin Lung Cancer 2006;7:381-384 (Pubitemid 44043546)
14. Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562xe nografts in nude mice. Cancer Res 2003;63:375-381 (Pubitemid 36152495)
15. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 2007;110:2309-2315 (Pubitemid 47523149)
16. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
17. Rosenberg L. Pancreatic cancer: a review of emerging therapies. Drugs 2000;59:1071-1089 (Pubitemid 30339131)
18. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-2413 (Pubitemid 27251144)
19. Moore MJ. Brief communication: a new combination in the treatment of advanced pancreatic cancer. Semin Oncol 2005;32:5-6. (Pubitemid 41785430)
20. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000;7:421-427 (Pubitemid 30736789)
21. Lutz MP, Esser IB, Flossmann-Kast BB, et al. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-508 (Pubitemid 28414054)
22. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008;27:6365-6375
23. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652-4661 (Pubitemid 44297818)
24. Bankert RB, Egilmez NK, Hess SD. Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol 2001;22:386-393 (Pubitemid 32673645)
25. Perez-Soler R, Kemp B, Wu QP, et al. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000;6:4932-4938 (Pubitemid 32110439)
26. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther 20 09;85:217-221
27. Song D, Chaerkady R, Tan AC, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 2008;7:3275-3284
28. Trevino JG, Summy JM, Lesslie DP, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 2006;168:962-972 (Pubitemid 43327748)
29. Jallal H, Valentino ML, Chen G, Boschelli F, Ali S, Rabbani SA. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, andmetastasis in vitro and in vivo. Cancer Res 2007;67:1580-1588 (Pubitemid 46383382)
30. Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005;65:5358-5364 (Pubitemid 40827349)
31. Tan AC, Naiman DQ, Xu L, Winslow RL, Geman D. Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics 2005;21:3896-3904 (Pubitemid 41535505)
32. Finn RS. Targeting Src in breast cancer. Ann Oncol 2008;19:1379-1386
33. Boyer B, Bourgeois Y, Poupon MF. Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene 2002;21:2347-2356 (Pubitemid 34407294)
34. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res 2007;13:7232-7236
35. Price ND, Trent J, El-Naggar AK, et al. Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci US A 2007;104:3414-3419 (Pubitemid 46364173)
36. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5:436-446 (Pubitemid 40791486)
37. Dunlap SM, Celestino J, Wang H, et al. Insulin-like growth factor binding protein 2p romotes glioma development and progression. Proc Natl Acad Sci USA 2007;104:11736-11741 (Pubitemid 47175082)
38. Parissenti AM, Hembruff SL, Villeneuve DJ, Veitch Z, Guo B, Eng J. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anticancer Drugs 2007;18:499-523. (Pubitemid 46597406)
39. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 2001;20:1152-1163 (Pubitemid 32226241)
40. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. Clin Cancer Res 2007;13:4233-4244
41. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-2008 (Pubitemid 34270888)
42. Chen T, Wang Z, Green T, Taylor C. Src tyrosine kinase as a therapeutic target in ovarian cancer and multidrug-resistant ovarian cancer. In: AACRNCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26 San Francisco, CA; 2007.
43. Tabernero J, Cervantes A, Hoekman K, et al. Phase I study of AZD0530, an oral potent inhibitor of Src kinase: First demonstration of inhibition of Src activity in human cancers. In: ASCO Annual Meeting Proceedings; 2007 June 1st - 5th.; Chicago, Illinois; 2007. p. 3520.